Compare CLNE & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLNE | QTTB |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 447.1M | 450.1M |
| IPO Year | 2006 | 2018 |
| Metric | CLNE | QTTB |
|---|---|---|
| Price | $1.47 | $8.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $4.01 | ★ $39.60 |
| AVG Volume (30 Days) | ★ 1.2M | 827.2K |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $341,599,000.00 | $53,737,000.00 |
| Revenue This Year | $1.41 | N/A |
| Revenue Next Year | $2.08 | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $1.91 |
| 52 Week High | $3.11 | $23.57 |
| Indicator | CLNE | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 30.86 |
| Support Level | N/A | $5.12 |
| Resistance Level | $1.84 | $16.85 |
| Average True Range (ATR) | 0.04 | 0.70 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 1.85 | 22.26 |
Clean Energy Fuels Corp is a natural gas marketer and retailer operating in the United States and Canada. The company supplies compressed natural gas and liquefied natural gas for the United States (U.S.) and Canadian transportation markets. The majority of revenue is generated within the U.S. and mostly consists of compressed natural gas. The firm operates by purchasing natural gas from local utilities; compressing, cooling, or liquefying it at company-owned plants; and selling natural gas products through company-owned or customer-owned fueling stations. It also builds, operates, and maintains natural gas fueling stations for customers.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).